|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Cell of origin, germinal center versus nongerminal center, determined by immunohistochemistry on tissue microarray, does not correlate with outcome in patients with relapsed and refractory DLBCL显示文摘 | Moskowitz CH Zelenetz AD Kewalramani T | 2005 | Blood2005，106，10： | 1 |
| 2 | PD-1 blockade with the rnonoclonal antibody pembrolizumab (MK-3475) in patients with classical hodgkin lymphoma after brentuximab vedotin failure: pre- liminary results from a phase lb study (KEYNOTE-013)显示文摘 | Moskowitz CH Ribrag V Michot J | 2014 | Blood2014，124，21： | 1 |
| 3 | Effectiveness of high dose chemoradiotherapy and autologous stem cell transplantation for patients with biopsy-proven primary refractory Hodgkin disease显示文摘 | Moskowitz CH Kewalramani T Nimer SD | 2004 | Br J Haemato12004，124，5： | 1 |
| 4 | Ifosfamide, carboplatin, and etoposide: a highly effective cytoreduction and peripheral-blood progenitor-cell mobilization regimen for transplant-eligible patients with non-Hodgkin's lymphoma 显示文摘 | Moskowitz CH Bertino JR Glassman JR | 1999 | J Clin Oncol1999，17，： | 1 |
| 5 | 2-step comprehensive high-dose chemoradiothcrapy second-line program for relapsed and re- fractory Hodgkin disease: Analysis by intent to treat and development of a prognostic model 显示文摘 | Moskowitz CH Nimer SD Zelenetz AD | 2001 | Blood2001，97，3： | 1 |
| 6 | Risk-adapted dose- dense immunochemotherapy determined by interim FDG-PET in Advanced-stage diffuse large B-Cell lymphoma显示文摘 | Moskowitz CH Schoder H Teruya-Feldstein J | 2010 | J Clin Oncol2010，28，11： | 1 |
| 7 | Maintaining the dose intensity of ICE chemotherapy with a thrombopoietic agent, PEG-rHuMGDF, may confer a survival advantage in relapsed and refractory aggressive non-Hodgkin lymphoma显示文摘 | Moskowitz CH Hamlin PA Gabrilove J | 2007 | Ann Oncol2007，18，： | 1 |
| 8 | Cell of origin, germinal center versus nongerminal center, determined by immunohistochemistry on tissue microarray, does not correlate with outcome in patients with relapsed and refractory DLBCL显示文摘 | Moskowitz CH Zelenetz AD Kewalramani T | 2005 | Blood2005，106，： | 1 |
| 9 | Correlation of quality measures with estimates of treatment effect in meta-analyses of randomized controlled trials显示文摘 | Balk EM Bonis PA Moskowitz H Schmid CH Ioannidis JP and Wang C | 2002 | JAMA2002，287，： | 1 |
| 10 | Ifosfamide, carboplatin,and etoposide: a highly eVective cytoreduction and peripheralblood progenitor-cell mobilization regimen for transplant-eligible patients with non-Hodgkin's lymphoma 显示文摘 | Moskowitz CH Bertino JR Glassman JR | 1999 | J Clin Oncol1999，17，12： | 1 |
| 11 | Risk- adapted dose-dense immunochemotherapy determined by interim FDG-PET in advanced-stage diffuse large B-Cell lymphoma显示文摘 | Moskowitz CH SchSder H Teruya-Feldstein J | 2010 | J Clin Oncol2010，28，11： | 1 |
| 12 | Riskadapteddose-dense immunochemotherapy determined by interimFDG-PET in advanced-stage diffuse large B-cell lymphoma显示文摘 | Moskowitz CH Schoeder H Teruya-Feldstein JA | 2010 | JClin Oncol2010，28，11： | 1 |
| 13 | Ifosfamide, carboplatin, and etoposide: a highly effective cytoreduction and peripheral-blood progenitor-cell mobilization regimen for transplant-eligible patients with non-Hodgkin's lymphoma 显示文摘 | Moskowitz CH Bertino JR Glassman JR | 1999 | J Clin Oncol1999，17，12： | 1 |
| 14 | Controversies in the treatment of lymphoma with autologous transplantation显示文摘 | Moskowitz AJ Moskowitz CH | 2009 | Oncologist2009，14，11： | 1 |
| 15 | A 2 -step comprehensivehigh-dose chemoradiotherapy second-line program for relapsedof refractory Hodgkin disease, analysis by intent to treat anddevelopment of a prognostic modd显示文摘 | Moskowitz CH Nimer SD Zelenetz AD | 2001 | Blood2001，97，3： | 1 |
| 16 | Ifosfamide, carbopl- atin, and etoposide: a highly effective cytoreduction and peripher- al-blood progenitor-cell mobilization regi-men for transplant-eli- gible patients with non-Hodgkin's lymphoma显示文摘 | Moskowitz CH BertinoJR GlassmanJR | 1999 | J Clin Oncol1999，17，12： | 1 |
| 17 | Pretreatment prognostic factors and outcome in patients with relapsed or primary-refractory diffuse large B -cell lymphoma treated with second-line chemotherapy and autologous stem cell transplantation 显示文摘 | Moskowitz CH | 2006 | Ann Oncol2006，17，4： | 1 |
| 18 | CD5 negative, Cyclin Dl-positive diffuse large B-cell lymphoma (DLBCL) presenting as ruptured spleen 显示文摘 | Teruya-Feldstein J Gopalan A Moskowitz CH | 2009 | Appl Immunohistochem Mol Morphol2009，17，3： | 1 |
| 19 | Ifosfamide,car-boplatin,and etoposide:a highly effective cytoreduction and pe-ripheral-blood progenitor-cell mobilization regimen for transplant-eligible patients with non-Hodgkin's lymphoma显示文摘 | Moskowitz CH Bertino JR Glassman JR | 1999 | J Clin On-col1999，17，12： | 1 |
| 20 | Cell of origin,germinal center versus nongerminal center,determined by immunohistochemistry on tissue microarray,does not correlate with outcome in patients with relapsed and refractory DLBCL显示文摘 | Moskowitz CH Zelenets AD Kewalramani T | 2005 | Blood2005，106，10： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员